Merck & Co., Inc: Constipation trials
The registry lists 12 Constipation studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 2 5Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901341Phase 3Results posted
- Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901328Phase 3Results posted
- Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901302Phase 3Results posted
- Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01696643Phase 3Results posted
- Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedNCT01275755Phase 2Results posted
- Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedNCT01207427Phase 2Results posted
- Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With OpioidTerminatedNCT00331045Phase 2
- Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00259922Phase 3
- Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00256932Phase 3
- Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00241722Phase 3
- Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain SubjectsCompletedNCT00135577Phase 2
- Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain MedicationCompletedNCT00101998Phase 2